You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2-positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HER2-positive Gastric Cancer, Immunotherapy Trial in Shanghai (Disitamab Vedotin combined with fruquintinib and Tislelizumab)

Recruiting
  • HER2-positive Gastric Cancer
  • Immunotherapy
  • Disitamab Vedotin combined with fruquintinib and Tislelizumab
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 8, 2023

HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer Trial in Beijing (KN026, KN046, XELOX)

Not yet recruiting
  • HER2-positive Colorectal Cancer
  • HER2-positive Biliary Tract Cancer
  • Beijing, State*, China
    Peking University cancer hospital & institution
Aug 2, 2023

HER2-positive Locally Advanced Resectable Gastric Cancer Trial (KN026, KN046, XELOX)

Not yet recruiting
  • HER2-positive Locally Advanced Resectable Gastric Cancer
  • (no location specified)
Sep 3, 2023

Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2

Recruiting
  • HER2-positive Breast Cancer
  • Early-stage Breast Cancer
  • pyrotinib combined with Capecitabine
  • treatment of physician's choice
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Sep 6, 2023

HER2-positive Advanced Breast Cancer Trial (DP303c, Trastuzumab, Vinorelbine Tartrate)

Not yet recruiting
  • HER2-positive Advanced Breast Cancer
  • (no location specified)
Jun 4, 2023

HER2-positive Breast Cancer Trial in Shanghai (68Ga/131I-SGMIB-5F7)

Not yet recruiting
  • HER2-positive Breast Cancer
  • 68Ga/131I-SGMIB-5F7
  • Shanghai, China
    Huashan Hospital
Aug 1, 2023

HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma Trial (Trastuzumab deruxtecan)

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer
  • HER2-positive Gastroesophageal Junction Adenocarcinoma
  • Trastuzumab deruxtecan
  • (no location specified)
Aug 11, 2023

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811, Ramucirumab / Paclitaxel/

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
  • SHR-A1811
  • Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
  • (no location specified)
Nov 6, 2023

HER2-positive Advanced Solid Tumors Trial in Shanghai (DP303c)

Recruiting
  • HER2-positive Advanced Solid Tumors
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 10, 2023

HER2-positive Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Miami (Discontinuation of Anti-HER-2 Maintenance

Recruiting
  • HER2-positive Metastatic Breast Cancer
  • Stage IV Breast Cancer
  • Discontinuation of Anti-HER-2 Maintenance Treatment
  • Miami, Florida
    University of Miami
Jul 17, 2023

HER-2 Positive Advanced Solid Tumors Trial (D3L-001)

Not yet recruiting
  • HER-2 Positive Advanced Solid Tumors
  • D3L-001
  • (no location specified)
Jul 20, 2023

HER2 Positive Advanced Solid Tumors Trial (HypoSti.CAR-HER2 T cells, Albumin-bound paclitaxel, Cyclophosphamide)

Not yet recruiting
  • HER2 Positive Advanced Solid Tumors
  • HypoSti.CAR-HER2 T cells
  • +2 more
  • (no location specified)
Jan 12, 2023

Breast Cancer Female Trial (Pyrotinib and Trastuzumab)

Not yet recruiting
  • Breast Cancer Female
  • Pyrotinib and Trastuzumab
  • (no location specified)
Sep 11, 2023

Early On-treatment Transcriptional Profiling as Predictor of

Recruiting
  • HER2-positive Breast Cancer
  • +2 more
  • Trastuzumab (neoadjuvant)
  • +2 more
  • Hospitalet de Llobregat, Barcelona, Spain
    Institut Català d'Oncologia l'Hospitalet
Jun 12, 2023

HER2-positive Breast Cancer Trial in Guanzhou (Eribulin mesylate injection?Pertuzumab?Trastuzumab)

Recruiting
  • HER2-positive Breast Cancer
  • Eribulin mesylate injection、Pertuzumab、Trastuzumab
  • Guanzhou, Guangdong, China
    LI YuDong
Jul 13, 2023

HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy Trial (SHR-A1811,

Not yet recruiting
  • HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
  • (no location specified)
Nov 7, 2023

Breast Cancer Stage I Trial (Capecitabine,Pyrotinib)

Not yet recruiting
  • Breast Cancer Stage I
  • (no location specified)
May 7, 2023

HER2 Positive Early Breast Cancer Trial in Shanghai (Docetaxel, carboplatin, Trastuzumab)

Recruiting
  • HER2 Positive Early Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center Shanghai, China, 200032
Jun 6, 2023

Breast Cancer, HER2-positive Breast Cancer Trial in Zhengzhou (Albumin paclitaxel+trastuzumab+pyrrolitinib,

Active, not recruiting
  • Breast Cancer
  • HER2-positive Breast Cancer
  • Zhengzhou, Henan, China
    Henan cancer hospital
Jun 23, 2023

HER2-positive Advanced Breast Cancer Patients Treated With ADC

Recruiting
  • Breast Cancer
  • HER2 expression of circulating tumor cells
  • Beijing, Beijing, China
    The Fifth Medical Center of PLA General Hospital
Apr 18, 2023

HER2-positive Breast Cancer Trial (Standard of Care Adjuvant Breast Radiation, Standard of Care HER2-targeted Therapy Without

Not yet recruiting
  • HER2-positive Breast Cancer
  • Standard of Care Adjuvant Breast Radiation
  • Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation
  • (no location specified)
Jan 20, 2023

HER2-Positive Cancer Trial in Wuhan

Active, not recruiting
  • HER2-Positive Cancer
    • Wuhan, Hubei, China
      TongjiHospital
    Sep 7, 2022

    Sentinel Lymph Node Biopsy in Initially Lymph Node-positive,

    Completed
    • Breast Cancer
    • Sentinel Lymph Node
    • Test cohort
    • Fuzhou, Fujian, China
      Chuan Wang
    Nov 25, 2023

    Breast Cancer Invasive Trial (pyrotinib)

    Not yet recruiting
    • Breast Cancer Invasive
    • (no location specified)
    Jun 18, 2023

    HER2-positive Breast Cancer Trial in Chengdu (Recombinant anti-HER2 humanized mAb conjugate for injection.R&D code: B003.)

    Active, not recruiting
    • HER2-positive Breast Cancer
    • Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.
    • Chengdu, Sichuan, China
      West China Hospital of Sichuan University
    Jan 30, 2023